Steven Deeks, MD

Phone: 415-476-4082 ext. 330
UCSF Box: 0874
Email: [email protected]
UCSF Profile

Project Sponsor Location(s) Topics Start End
Immediate Salvage Therapy w/ Combination ART plus T-20 vs. A 16 Week Structured Treatment Interruption Followed by Combination Therapy plus T-20 Trimeris, Inc. United States HIV/AIDS, Pharmacology and Drug Treatment
Interruption of Enfuvirtide in Patients Experiencing an Incomplete Virologic Response to Enfuvirtide-Based Combination Antiretroviral Regimen Hoffman-LaRoche, Ltd. United States HIV/AIDS, Pharmacology and Drug Treatment
Treatment Intensification for Drug-Resistant HIV NIH National Institute of Allergy and Infectious Disease United States HIV/AIDS
Enfuvirtide Intensification for Multi-Drug Resistant HIV California HIV/AIDS Research Program United States Zoonosis, Emerging Disease, and Drug Resistance, HIV/AIDS, Pharmacology and Drug Treatment
Enfuvirtide Treatment Intensification in Patients with Multi-Drug Resistant HIV Hoffman-LaRoche, Ltd. United States HIV/AIDS, Pharmacology and Drug Treatment
T Regulatory Cells and T Cell Activation in HIV Disease NIH National Institute of Allergy and Infectious Disease United States HIV/AIDS, Immunology
HIV Controllers: A Potential Model for HIV Eradication American Foundation for AIDS Research (AmFAR) United States HIV/AIDS, Immunology
San Francisco National Clinical Trial Center, ESPIRIT University of Minnesota Morocco; Japan; Singapore; Thailand; Israel; Austria; Belgium; Denmark; France; Germany; Ireland; Italy; Netherlands; Norway; Poland; Portugal; Spain; United Kingdom; Argentina; Brazil; Canada; Australia HIV/AIDS, Pharmacology and Drug Treatment
Elite Controllers Until There's a Cure Foundation United States HIV/AIDS, Immunology, Genetics
Long Term Follow-Up of Patients Enrolled in Clinical Trials (#A-9602, A-9604, A-9801) Using Retroviral Gene Based Therapies / AIDS related research Cell Genesys, Inc. United States HIV/AIDS
Atripla Adherence and Resistance Relationships [I] Gilead Sciences, Inc. United States HIV/AIDS, Treatment Adherence
Atripla Adherence and Resistance Relationships [II] Bristol-Myers Squibb Company United States HIV/AIDS, Treatment Adherence
Raltegravir Intensification in Antiretroviral-Treated Patients Exhibiting a Suboptimal CD4+T Cell Response Merck and Co., Inc. United States HIV/AIDS, Immunology
Innate Effector Function and HIV-1 Control Wistar Institute United States HIV/AIDS, Immunology
International Network for Strategic Initiatives in Global HIV Trials/ ICR INSIGHT U.S. Department of Veterans Affairs South Africa; Mali; Brazil; Peru HIV/AIDS, Drug and Diagnostics Development
Master Agreement: International Network for Strategic Initiatives in Global HIV Trials/ICR INSIGHT U.S. Department of Veterans Affairs Uganda; South Africa; Mali; Nigeria; China; Malaysia; Thailand; Mexico; Argentina; Brazil; Chile; Peru; Uruguay HIV/AIDS
HIV Entry Inhibitors: A New Therapeutic Option University of Pennsylvania United States HIV/AIDS, Immunology
UCSF/Ragon Collaboration on HIV "Elite" Controllers Massachusetts General Hospital United States HIV/AIDS, Drug and Diagnostics Development, Immunology, Genetics
Preventing the Establishment of Enfuvirtide-Resistance in the Latent Reservoir NIH National Institute of Allergy and Infectious Disease United States HIV/AIDS
Disulfiram to Accelerate Decay in HIV Reservoirs in ART Treated Patients Johns Hopkins University United States HIV/AIDS
The Impact of Early Antiretroviral Therapy on HIV Persistence and Inflammation NIH National Institute of Allergy and Infectious Disease United States HIV/AIDS, Pharmacology and Drug Treatment
The Impact of Early Antiretroviral Therapy on HIV Persistence and Inflammation NIH National Institute of Allergy and Infectious Disease United States HIV/AIDS
Characterizing the Role of Immune Activation in HIV Persistence University of California Los Angeles (UCLA) United States HIV/AIDS, Immunology
AIDS Clinical Trials Network (ACTG)-Deeks (Co-Vice Chair) A5296 Brigham and Women's Hospital United States HIV/AIDS, Noncommunicable and/or Chronic Disease, Pharmacology and Drug Treatment
Treating HIV-infected Elite Controllers as a Model of HIV Remission Gilead Sciences, Inc. United States HIV/AIDS
Task Order: R24 for the CFAR-Network for the Integrated Clinical Sciences, CNICS University of Alabama System United States
Short-Term Disulfiram Administration to Reverse Latent HIV Infection Monash University United States HIV/AIDS, Pharmacology and Drug Treatment
HIV Persistence after Successful CCR5-Depleted Stem Cell Transplantation American Foundation for AIDS Research (AmFAR) United States HIV/AIDS
EraMune Project Northwestern University United States
HIV Specific T-Cell Responses in Rectal Mucosa University of California Davis United States HIV/AIDS
Identifying and Targeting HIV Persistence in T Cell Subsets during ART Vaccine and Gene Therapy Institute of Florida United States HIV/AIDS
Effects of CCR5 - delta-32 Heterozygosity on the HIV-1 Reservoir Vitalant Research Institute United States HIV/AIDS, Immunology, Genetics
Core B: Specimen Repository Core Case Western Reserve University United States
Epigenetic Regulation of HIV Latency J. David Gladstone Institutes United States HIV/AIDS
Impact of Sex-Based Differences on HIV Reservoir Size and Immune Activation Massachusetts General Hospital United States HIV/AIDS, Women's Health
Gender-specific Differences Affecting Reactivation of Latent HIV in Treated Patients Case Western Reserve University United States HIV/AIDS, Immunology, Women's Health
Characterization of the HIV-1 Latent Reservoir in CCR5-Delta 32 Heterozygotes Vitalant Research Institute United States HIV/AIDS
Identifying and targeting HIV persistence in T Cell subsets during ART Vaccine and Gene Therapy Institute of Florida United States Drug and Diagnostics Development, Immunology, Genetics
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) University of Minnesota Tanzania; Zambia; Morocco; South Africa; Mali; Thailand; Greece; Argentina; Brazil; Chile; Peru HIV/AIDS
Impact of HIV-Associated Inflammation on Disease NIH National Institute of Allergy and Infectious Disease United States HIV/AIDS
DARE: Delaney AIDS Research Enterprise to Find a Cure NIH National Institute of Allergy and Infectious Disease Sweden; Australia HIV/AIDS
Master Agreement: R24 for the CFAR-Network for the Integrated Clinical Sciences, CNICS University of Alabama System United States HIV/AIDS
Enhancing Control of HIV by Inhibiting TRAIL Mayo Foundation United States HIV/AIDS, Drug and Diagnostics Development, Immunology
Impact of interferon-alpha inhibition on immune function and viral persistence in HIV disease Bill & Melinda Gates Foundation United States HIV/AIDS, Immunology
Validation of Existing Ultra-Sensitive Assays for Quantifying HIV Persistence Vitalant Research Institute United States HIV/AIDS, Drug and Diagnostics Development
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT): START University of Minnesota South Africa; Mali; Brazil; Peru HIV/AIDS, Drug and Diagnostics Development
Measuring the Latent reservoir for HIV Johns Hopkins University United States HIV/AIDS, Drug and Diagnostics Development
GS-US-382-3961: A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers Gilead Sciences, Inc. United States HIV/AIDS, Drug and Diagnostics Development
Combination immune checkpoint blocker inhibition to eliminate HIV latency University of Melbourne, The United States HIV/AIDS, Drug and Diagnostics Development
Programming Long Term Durable HIV-1 Specific T cell Responses University of Pennsylvania United States HIV/AIDS, Immunology
Viral control mechanisms of HIV-specific T cells in HIV-infected lymph node University of Pennsylvania United States HIV/AIDS
Deeks Order CNICS: June 2014-Aug 2016 University of Alabama System United States HIV/AIDS
Delaney AIDS Research Enterprise to Cure HIV NIH National Institute of Allergy and Infectious Disease United States HIV/AIDS, Drug and Diagnostics Development
Therapeutic vaccination and PD-1 blockade in treated HIV disease NIH National Institute of Allergy and Infectious Disease United States HIV/AIDS